This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. 1. To evaluate the safety, tolerability, and immunogneiciyt of 3 VRC HIV-1 DNA-6-plasmid vaccine doses at 4.0 mg/dose followed by VRC HIV-1 rAd5 vaccine boost at 1`0^10 PU in HIV-1 uninfected adults. 2. To evaluate the frequency of humoral immune responses to 3 doses of the HIV-1 DNA vaccine followed by the adenoviral vector vaccine. 3. To assess the relationship between prior Ad5 neutralizing antibody and immunogenicity as assessed by IFN-y ELISpot, ICS, and neutralizing antibody assay. 4. To evaluate the social impacts of trial participation.
Showing the most recent 10 out of 515 publications